> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Penumbra Sales Rise 15% But Operating Income Is Flat At $130.0 Million, And Boston Scientific Deal Moves To 2027
- URL: https://www.bullished.co/penumbra-sales-rise-15-but-operating-income-is-flat-at-130-0-million-and-boston-scientific-d16ba56b/
- Published: 2026-10-29T21:37:21.000Z
- Updated: 2026-10-29T21:37:21.000Z
- Description: Nine-month operating income matched last year as SG&A climbed 23.5%, and Penumbra now expects its merger to close in early 2027.
- Author: Matteo Parrino
- Tags: Deals, PEN, Industry: Healthcare

[Penumbra](https://www.bullished.co/tag/pen/), which makes devices that remove blood clots, earned [$130.0 million in operating income](https://www.sec.gov/Archives/edgar/data/0001321732/000132173226000043/pen-20260930.htm?ref=bullished.co) for the first nine months of 2026, the same as a year earlier, even though revenue rose to $1,174.9 million from $1,018.3 million. The 10-Q, filed Thursday, also pushes the expected close of its Boston Scientific merger to early 2027.

## Sales grew, spending ate the gain

Revenue for the nine months rose 15.4%. Thrombectomy sales, the clot-removal line, climbed 14.3% to $792.1 million, and embolization and access rose 17.8% to $382.9 million. Gross margin improved to 68.0% from 66.8%.

Selling, general and administrative costs rose $113.2 million, or 23.5%, to $595.5 million. The filing cites a $41.4 million rise in personnel costs, a $23.5 million rise in acquisition-related expenses tied to the pending Boston Scientific deal, and a $16.1 million rise in marketing-event costs.

Net income for the nine months fell to $109.7 million from $130.3 million. The effective tax rate rose to 23.9% from 7.9%, which the filing attributes to smaller excess tax benefits from stock-based compensation.

In the third quarter alone, revenue rose 15.6% to $410.1 million and operating income was $50.7 million, against $48.8 million a year earlier. Penumbra said in its [earnings release](https://www.sec.gov/Archives/edgar/data/0001321732/000132173226000042/pen-93026xexhibit991.htm?ref=bullished.co) that it will give no full-year guidance and hold no conference call because of the pending acquisition.

## A later closing for the $14.5 billion deal

The [prior quarter's 10-Q](https://www.sec.gov/Archives/edgar/data/0001321732/000132173226000037/pen-20260630.htm?ref=bullished.co) said the merger was expected to close by the end of 2026\. The new filing says early 2027, subject to regulatory approvals and other customary conditions.

Boston Scientific agreed in January to buy Penumbra at $374 per share, an enterprise value of about $14.5 billion. Holders can elect cash or 3.8721 Boston Scientific shares, with proration so the total is about 73% cash and 27% stock. Penumbra's stockholders have approved the deal.

Penumbra would owe Boston Scientific a $525.0 million termination fee under specified circumstances. Boston Scientific would owe Penumbra $900.0 million if the agreement ends under certain circumstances.

## The business behind the numbers

Penumbra develops and sells devices for ischemic stroke, pulmonary embolism and acute limb ischemia, selling mostly direct to hospitals. For 2025 it reported revenue of $1,403.7 million, of which thrombectomy was $947.9 million. Its market value was $12.5 billion as of Thursday's report.

Operating cash flow for the nine months rose to $174.6 million from $152.2 million, and cash and equivalents stood at $254.3 million on September 30.

The company's annual goodwill impairment review is set for October 31, and the early-2027 close hinges on regulatory approvals.

### Sources

- [10-Q Filing — Penumbra (PEN)](https://www.sec.gov/Archives/edgar/data/0001321732/000132173226000043/pen-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Penumbra (PEN), Q2 FY2026 filed 2026-07-30 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001321732/000132173226000037/pen-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, pen-93026xexhibit991.htm) — Penumbra, filed 2026-10-29](https://www.sec.gov/Archives/edgar/data/0001321732/000132173226000042/pen-93026xexhibit991.htm?ref=bullished.co) — SEC EDGAR
- [Penumbra: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/penumbra-q3-earnings-snapshot/616-37b60236-7465-4585-a990-21de6a3396f7?ref=bullished.co) — Associated Press
- [Penumbra GAAP EPS of $1.07 misses by $0.11, revenue of $410.1M beats by $7.73M (PEN:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4660870-penumbra-gaap-eps-of-1%5F07-misses-by-0%5F11-revenue-of-410%5F1m-beats-by-7%5F73m?ref=bullished.co) — seekingalpha.com
- [Penumbra: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/penumbra-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [Penumbra: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/penumbra-q3-earnings-snapshot/616-37b60236-7465-4585-a990-21de6a3396f7?ref=bullished.co) — Associated Press
- [Penumbra: Q3 Earnings Snapshot | khou.com](https://www.khou.com/article/syndication/associatedpress/penumbra-q3-earnings-snapshot/616-37b60236-7465-4585-a990-21de6a3396f7?ref=bullished.co) — Associated Press

### More on Penumbra

- [Penumbra Revenue Climbs 15.6% To $410.1 Million, But Net Income Slips To $42.3 Million](https://www.bullished.co/penumbra-revenue-climbs-15-6-to-410-1-million-but-net-income-slips-to-42-3-million-14b9a9ea/)

[All Penumbra (PEN) coverage →](https://www.bullished.co/tag/pen/)